AstraZeneca takes a chance on the STING pathway with F-star
After a slew of Big Pharma companies and biotechs walked away from the STING pathway in the last few years, AstraZeneca is approaching the field with a new bet on the drug class’ next generation.
The British drugmaker is teaming up with F-star Therapeutics on a slate of preclinical STING inhibitor compounds, the companies announced Thursday morning. It’s a modest sum as these things go, with $12 million upfront and over $300 million in milestones, plus single-digit royalties.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.